Neutrolis received $4.46 million to develop therapeutics that target neutrophils and reduce severe immune responses in acute and chronic inflammatory diseases through engineered enzyme analogs.
Neutrolis received $4.46 million to develop therapeutics that target neutrophils and reduce severe immune responses in acute and chronic inflammatory diseases through engineered enzyme analogs.
